SEARCH

SEARCH BY CITATION

REFERENCES

  • 1
    Colgan TJ, McLachlin CM, Cotterchio M, Howlett R, Seidenfeld AM, Mai VM. Results of the implementation of liquid-based cytology SurePath in the Ontario screening program. Cancer (Cancer Cytopathol). 2004; 102: 362-367.
  • 2
    BD Diagnostics. The BD FocalPoint Slide Profiler. Franklin Lakes, NJ: BD Diagnostics; 2012. Available at: http://www.bd.com/tripath/labs/fp_screening.asp. Accessed August 8, 2012.
  • 3
    Cancer Care Ontario. The Ontario Cervical Screening Program 2003-2008. Toronto, Ontario: Cancer Care Ontario; 2012. Available at: https://www.cancercare.on.ca/pcs/screening/cervscreening/hcpresources/. Accessed August 7, 2012.
  • 4
    Wilbur DC, Black-Schaffer WS, Luff RD, et al. The Becton Dickinson FocalPoint GS Imaging System: clinical trials demonstrate significantly improved sensitivity for the detection of important cervical lesions. Am J Clin Pathol. 2009; 132: 767-775.
  • 5
    Kitchener HC, Blanks R, Dunn G, et al. Automation-assisted versus manual reading of cervical cytology (MAVARIC): a randomized controlled trial. Lancet Oncol. 2011; 12: 56-64.
  • 6
    Quality Management Program-Laboratory Services (QMP-LS). Accreditation Requirements and Guidance. Toronto, Ontario: QMP-LS, Ontario Medical Association; 2012. Available at: http://www.qmpls.org/LaboratoryAccreditation/OLARequirements.aspx. Accessed August 8, 2012.
  • 7
    Clinical and Laboratory Standards Institute (formerly the National Committee for Clinical Laboratory Standards [NCCLS]). A Framework for NCCLS Evaluation Protocols; A Report. NCCLS documentEP19-R. Wayne, PA: Clinical and Laboratory Standards Institute; 2009.
  • 8
    Sprinthall RC. Basic Statistical Analysis. 7th ed. Boston, MA: Pearson Education Group; 2003.
  • 9
    Hunt JL. New applications for old assays and the importance of validation. Cancer (Cancer Cytopathol). 2012; 120: 3-6.
  • 10
    BD Diagnostics. BD FocalPoint GS Imaging System [product insert]. Franklin Lakes, NJ: BD Diagnostics; 2012. Available at: http://www.bd.com/tripath/labs/fp_gs_system.asp. Accessed August 8, 2012.
  • 11
    British Association for Cytopathology. Recommended Code of Practice for Laboratories Participating in the UK Cervical Screening Programmes. London, United Kingdom: British Association for Cytopathology; 2012. Available at: http://www.britishcytology.org.uk/resources/resources.asp. Accessed August 27, 2012.
  • 12
    College of Medical Laboratory Technologists of Ontario (CMTLO). Practice Guidelines for Medical Laboratory Technologists Practicing in Cytology. Toronto, Ontario: CMTLO; 2008. Available at: http://www.cmlto.com/index.php?searchword= cytotechnologists&ordering=&searchphrase=all&Itemid=9999&option=com_search. Accessed August 8, 2012.
  • 13
    Kitchener HC, Blanks R, Cubie H, et al. MAVARIC a comparison of automation-assisted and manual cervical screening: a randomised controlled trial. Health Technol Assess. 2011; 15: iii-iv, ix-xi, 1-170.
  • 14
    Levi AW, Chhieng DC, Schofield K, Kowalski D, Harigopal M. Implementation of FocalPoint GS location-guided imaging system. Cancer (Cancer Cytopathol). 2012; 120: 126-133.
  • 15
    Denton KJ, Nuttall D, Cropper A, Desai M; on behalf of the British Association for Cytopathology. Implementation of “No further review” (NFR) using the BC FocalPoint Slide. Profiler. National Health Service Cervical Screening Programme Good Practice Guide No. 4. Sheffield, United Kingdom: National Health Service Cancer Screening Programmes; 2012.Available at: http://www.britishcytology.org.uk/uploads/NHSCSP%20GPG4%20No%20further%20review.pdf. Accessed August 27, 2012.